Cargando…

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo

BACKGROUND: Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with chemotherapy. In this study, we investigated the role of complement activation in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Yi-Fan, Ajona, Daniel, Corrales, Leticia, Lopez-Picazo, Jose M, Gurpide, Alfonso, Montuenga, Luis M, Pio, Ruben
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893457/ https://www.ncbi.nlm.nih.gov/pubmed/20529262 http://dx.doi.org/10.1186/1476-4598-9-139

Ejemplares similares

Complement in Metastasis: A Comp in the Camp
por: Ajona, Daniel, et al.
Publicado: (2019)

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
por: Larrayoz, Marta, et al.
Publicado: (2014)

Complementing the Cancer-Immunity Cycle
por: Pio, Ruben, et al.
Publicado: (2019)

The Complement System in Ovarian Cancer: An Underexplored Old Path
por: Senent, Yaiza, et al.
Publicado: (2021)

Complement C4d-specific antibodies for the diagnosis of lung cancer
por: Ajona, Daniel, et al.
Publicado: (2017)

Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
por: Ajona, Daniel, et al.
Publicado: (2015)

A model based on the quantification of complement C4c, CYFRA 21–1 and CRP exhibits high specificity for the early diagnosis of lung cancer
por: AJONA, DANIEL, et al.
Publicado: (2021)

Molecular biomarkers in early stage lung cancer
por: Rodríguez, María, et al.
Publicado: (2021)

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations
por: Aramburu, Ander, et al.
Publicado: (2015)

Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer
por: Valles, Iñaki, et al.
Publicado: (2012)

IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
por: Senent, Yaiza, et al.
Publicado: (2021)

Editorial: The Role of Complement in Tumors
por: Rolfe, Barbara E., et al.
Publicado: (2020)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

Cetuximab in small bowel adenocarcinoma: a new friend?
por: Santini, D, et al.
Publicado: (2010)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
por: Valencia, Karmele, et al.
Publicado: (2022)

DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC)
por: Carazo, Fernando, et al.
Publicado: (2020)

Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients
por: Grbesa, Ivana, et al.
Publicado: (2015)

Reply: Cetuximab in small bowel adenocarcinoma: a new friend?
por: Overman, M J, et al.
Publicado: (2010)

Cetuximab and biomarkers in non-small-cell lung carcinoma
por: Patil, Nitin, et al.
Publicado: (2012)

Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
por: Pio, Ruben, et al.
Publicado: (2010)

The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients
por: Macías, Mónica, et al.
Publicado: (2019)

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
por: Vicent, S, et al.
Publicado: (2004)

In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas
por: de Boer, Esther, et al.
Publicado: (2015)

EventPointer: an effective identification of alternative splicing events using junction arrays
por: Romero, Juan P., et al.
Publicado: (2016)

Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells
por: Shigeta, Kohei, et al.
Publicado: (2013)

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer
por: Fusco, Juan Pablo, et al.
Publicado: (2018)

Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
por: Villalba, Maria, et al.
Publicado: (2019)

Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
por: Wu, Zhiwen, et al.
Publicado: (2019)

SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays
por: Anton, Miguel A, et al.
Publicado: (2008)

Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
por: Aggarwal, Charu, et al.
Publicado: (2009)

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
por: Bocanegra, Ana, et al.
Publicado: (2023)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Enhanced Antitumor Effects of Epidermal Growth Factor Receptor Targetable Cetuximab-Conjugated Polymeric Micelles for Photodynamic Therapy
por: Chang, Ming-Hsiang, et al.
Publicado: (2018)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma
por: Vallejo-Díaz, Jesús, et al.
Publicado: (2016)

Ingeniería de servicios : para crear clientes satisfechos y lograr ventajas competitivas sustanciales y sostenibles
por: Picazo Manríquez, Luis Rubén
Publicado: (1992)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ud1q5ldoncbi880mih38887p0